http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kang, Byung Woog,Kim, Jong Gwang,Chae, Yee Soo,Lee, Yoo Jin,Lee, Soo Jung,Moon, Joon Ho,Sohn, Sang Kyun,Jung, Min Kyu,Jeon, Seong Woo,Jang, Yun-Jin,Seo, Jongduk,Lee, Yong Hyun,Kwon, Ohkyung,Chung, Ho M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.4
<P>The feasibility of a 3-week combination of S-1 and cisplatin as an adjuvant chemotherapy for patients with curatively resected gastric cancer was investigated.</P>
Hwang, In Gyu,Jang, Joung-Soon,Oh, Sung Yong,Lee, Suee,Kwon, Hyuk Chan,Lee, Gyeong Won,Go, Seil,Kang, Myoung Hee,Cha, Young Joo,Kang, Jung Hun M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.6
<P>Gemcitabine has been recognized as a standard chemotherapy in advanced pancreas cancer(APC). We conducted a phase II study of a triple combination regimen (GPT) consisting of gemcitabine (G), cisplatin(P) and erlotinib (T) in patients with APC.</P>
Shin, Sang Joon,Hwang, Jee Won,Ahn, Joong Bae,Rha, Sun Young,Roh, Jae Kyung,Chung, Hyun Cheol M. Nijhoff ; Kluwer Academic Publishers 2013 Investigational new drugs Vol.31 No.1
<P>The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has received considerable attention as a first-line treatment of advanced colorectal cancers. Difficulties associated with effectively monitoring the activity of this drug have prompted us to seek a pharmacodynamic marker suitable for defining the optimum biological dose and schedule of bevacizumab administration against colon cancer in early clinical trials.</P>
Hong, Yong Sang,Lee, Jeeyun,Kim, Kyu-pyo,Lee, Jae-Lyun,Park, Young Suk,Park, Joon Oh,Park, Se Hoon,Kim, Sun Young,Baek, Ji Yeon,Kim, Jee Hyun,Lee, Keun-Wook,Kim, Tae-You,Kim, Tae Won M. Nijhoff ; Kluwer Academic Publishers 2013 Investigational new drugs Vol.31 No.1
<P>To investigate the efficacy and safety of bevacizumab beyond first progression combined with doublet chemotherapy in patients with metastatic colorectal cancer.</P>
Lee, Seunghyun,Choi, Seung Hong,Ryoo, Inseon,Yoon, Tae Jin,Kim, Tae Min,Lee, Se-Hoon,Park, Chul-Kee,Kim, Ji-Hoon,Sohn, Chul-Ho,Park, Sung-Hye,Kim, Il Han M. Nijhoff ; Kluwer Academic Publishers 2015 Journal of neuro-oncology Vol.121 No.1
<P>The purpose of our study was to explore the difference between isocitrate dehydrogenase (IDH)-1/2 gene mutation-positive and -negative high-grade gliomas (HGGs) using histogram analysis of apparent diffusion coefficient (ADC) and normalized cerebral blood volume (nCBV) maps. We enrolled 52 patients with histopathologically confirmed HGGs with IDH1/2 (P) (n = 16) or IDH1/2 (N) (n = 36). Histogram parameters of ADC and nCBV maps were correlated with gene mutations by using the unpaired student's t test and multivariable stepwise logistic regression analysis. The mean ADC value was higher in the IDH1 (P) group than IDH1 (N) (1,282.8 vs. 1,159.6 mm(2)/s, P = .0113). In terms of the cumulative ADC histograms, the 10th and 50th percentile values were also higher in the IDH1 (P) than IDH1 (N) (P = .0104 and .0183, respectively). We observed a higher 90th percentile value (3.121 vs. 2.397, P = .0208) and a steeper slope between the 10th (C10) and 90th (C90) of cumulative nCBV histograms (0.03386 vs. 0.02425/%, P = .0067) in the IDH1 (N) group. Multivariate analysis showed that the mean ADC mean value (P = .0048), the C90 value (P = .0113), and the slope between C10 and C90 (P = .0049) were the significant variables in the differentiation of IDH1 (P) from IDH1 (N). In conclusion, histogram analysis of ADC and nCBV maps based on entire tumor volume can be a useful tool for distinguishing IDH1 (P) and IDH1 (N), and it predicts that IDH (P) tumors have a more heterogeneous microenvironment than IDH (N) ones.</P>
COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim, Hee Sung,Moon, Hyeong-Gon,Han, Wonshik,Yom, Cha Kyung,Kim, Woo Ho,Kim, Jun Ho,Noh, Dong-Young M. Nijhoff ; Kluwer Academic Publishers 2012 Breast cancer research and treatment Vol.132 No.1
<P>To determine the significance of (Cyclooxygenase 2) COX2 for clinical outcome in breast cancer, we analyzed the correlation between COX2 overexpression and survival in 687 patients with invasive breast cancer. Cytoplasmic immunoreactivity of COX2 was determined as positive in 325 of 687 (47.3%) invasive breast cancers. COX2 positivity was significantly correlated with high histologic grade, negative estrogen receptor (ER), high Ki67, luminal B and triple-negative tumors, Bcl2 negativity, and p53 overexpression. In univariate analysis, COX2 overexpression resulted in significantly shorter relapse-free survival (RFS) [hazard ratio (HR) 1.487, 95% CI 1.035-2.110, P = 0.032]. Multivariate analysis revealed no significant association between COX2 overexpression and either overall survival (OS) or RFS. Kaplan-Meier analysis of the whole patient group showed significantly reduced RFS in patients with high COX2 expression, compared to those that did not overexpress COX2 (91 vs. 162 months, P = 0.031). Stratified subgroup analysis by TNM stage disclosed marked differences in OS and RFS rates in Stage III patients. We observed a significant association of COX2 overexpression with shorter RFS in the ER-negative subgroup of Stage III patients. The results show that COX2 overexpression is a significant unfavorable prognostic factor in Stage III breast cancer, and provide selective criteria for COX2 inhibitor combinations for invasive breast cancer therapy.</P>
Yu, Jieun,Lee, Hyuk-Joon,Hur, Keun,Kwak, Mi Kyung,Han, Tae Su,Kim, Woo Ho,Song, Soo-Chang,Yanagihara, Kazuyoshi,Yang, Han-Kwang M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.1
<P>The prognosis of peritoneal carcinomatosis is regarded as poor because safe, effective therapeutic modalities are lacking. Intraperitoneal chemotherapy is one treatment option, involving the delivery of a high concentration of chemotherapeutic drugs into the abdominal cavity, but the severe side effects associated with such treatment are a major obstacle in clinical application. We evaluated the anti-cancer effects of intraperitoneal delivery of a thermosensitive polymeric hydrogel containing chemotherapeutics in an animal model of carcinomatosis. The progress of peritoneal carcinomatosis, introduced by injecting a luciferase-transfected human gastric cancer cell line (HSC44Luc) into the peritoneal cavity of nude mice, was quantitatively evaluated by in vivo bioluminescence imaging. Three days after intraperitoneal (IP) injection of HSC44Luc cells, treatment solutions were injected into the peritoneal cavity. Mice were categorized into four groups depending on treatment method; these were (1) a control PBS group (n?=?5), (2) a hydrogel-only group (n?=?5), (3) a paclitaxel solution (30?mg/kg) group (n?=?3), and (4) a hydrogel-with-paclitaxel (15?mg/kg) group (n?=?5). Quantitative photon counting was performed weekly in each animal. Mice were sacrificed on the 5th or 28th day after treatment, for pathologic evaluation. In vivo bioluminescence imaging showed that photon counts in the hydrogel-with-paclitaxel and paclitaxel solution groups were significantly lower than in the PBS group over the entire experimental period. Although neither group of responding mice showed any peritoneal nodules on the 28th day after treatment, only the paclitaxel solution group exhibited dilated edematous changes in the intestine; these side effects were absent in animals treated with hydrogel-with-paclitaxel group. In conclusion, a thermosensitive hydrogel containing paclitaxel may be a safe and effective treatment option for peritoneal carcinomatosis.</P>
Oh, Do-Youn,Lee, Keun Wook,Lee, Kyung-Hee,Sohn, Chang-Hak,Park, Young Suk,Zang, Dae Young,Ryoo, Hun-Mo,Song, Hong-Suk,Kim, Jin-Soo,Kang, Hye-Jin,Kim, Bong-Seog,Bang, Yung-Jue M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.3
<P>To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC).</P>
Jeeva, Subbiah,Kang, Se-Won,Lee, Yong-Seok,Jang, In Kwon,Seo, Hyung Chel,Choi, Tae-Jin M. Nijhoff ; Kluwer Academic Publishers 2012 Virus genes Vol.44 No.1
<P>Hepatopancreatic parvovirus (HPV) of shrimp is distributed worldwide and the entire genome of Thailand and Indian strains (PmDNV) and one Australian strain (PmergDNV) have now been reported. The complete nucleotide sequence of a HPV strain isolated from the fleshy prawn Fenneropenaeus chinensis in Korea (FcDNV) was determined and compared to previously reported sequences. The entire genome of FcDNV contains 6,336 nucleotides, with 40% G+C content, which is the biggest of the known HPV strains. The HPV genome has three open reading frames (ORFs) with a slight overlap between the first and second ORFs. The three ORFs encode the NS2 and NS1 proteins and VP that consist of 425, 578, and 820 amino acids, respectively. Among the three proteins, the NS1 protein shows the highest sequence similarity to the NS1 protein of other known HPV strains, followed by the NS2 protein and the VP protein. Phylogenetic analyses showed that HPV can be grouped into three genotypes, as previously reported, and FcDNV can be grouped as genotype I, with HPV strains isolated in Madagascar and Tanzania. The nucleotide sequences of the noncoding regions at the 5'- and 3'-ends of the plus-strand genome showed a Y-shaped hairpin structure and simple hairpin structure, respectively.</P>
Stereotactic radiosurgery for primary and metastatic sarcomas involving the spine.
Chang, U K,Cho, W I,Lee, D H,Kim, M S,Cho, C K,Lee, S Y,Jeon, D G M. Nijhoff ; Kluwer Academic Publishers 2012 Journal of neuro-oncology Vol.107 No.3
<P>The treatment for spinal sarcomas is difficult due to inadequate surgical margin and an inability to deliver high dose radiation. Advanced technology of stereotactic radiosurgery (SRS) enabled higher biological effective doses of radiation to be delivered to spinal sarcomas by hypofractionation method. The authors evaluated local control rate following SRS for primary and metastatic spinal sarcomas. Thirty-two spinal sarcomas (10 primary tumors, 22 metastatic tumors) in 27 patients were treated by SRS from November 2002 to September 2009. Patients were assessed for pain status, neurological status and radiological response by regular follow-up. Overall survival and local progression-free survival were calculated and prognostic factors were sought. Median tumor volume was 18.6 ml. Radiation doses to the tumor margins ranged from 16 to 45 Gy in one to three fractions, and the median single session equivalent dose was 21.8 Gy. Follow-up ranged from 4 to 68 months (median, 22 months). Overall median survival was 29 months and no related prognostic factors were identified. During follow-up, pain was controlled in 89.3% (25/28) lesions at 6 months, in 68.2% (15/22) at 1 year, and in 61.5% (8/13) at 2 years. Tumor volume was found to be significantly related to post-SRS pain control rate. Radiological evaluation showed that local control was maintained in 96.7% (29/30) lesions at 6 months, in 78.3% (18/23) at 1 year, and in 76.9% (10/13) at 2 years. Radiation dose and tumor volume were found to be related to radiological control at 24 months following SRS. Nine cases developed recurrence between 2 and 33 months, median local progression-free survival was 23 months. Age was found to be predictive of local progression-free survival (P = 0.009). SRS proved to be an effective modality for the local control of primary and metastatic spinal sarcomas, and age was significantly related to local recurrence.</P>